Cannabis Law Report

FEBRUARY 28, 2022

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. 1025, 1026 (2021) (reporting significant improvement of PTSD symptoms following treatment with MDMA in clinical trial); see also Alec J. Mitchell et al., Divito & Robert F. 11 × 11. 15 × 15.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

The Cannigma

JULY 1, 2022

There’s no doubt that the amount of information that is available about cannabis is at an all-time high – in 2020 alone, over 3,500 scientific articles were published on the topic. What if most of it is not based on the level of scientific certainty that cannabis marketing teams and media outlets would have us believe?

Research and Development 108

Research and Development Data THC Clinical Trials 108

Cannabis Law Report

OCTOBER 29, 2021

The highlights for the quarter are: As previously disclosed, on September 7, 2021, the Company announced the completion of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”) based investigational new drug, IGC-AD1, intended to alleviate certain symptoms of individuals who have Alzheimer’s disease.

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

The Cannigma

JUNE 24, 2021

The constant distractions, notifications, and social media outrages of the day can also boost your anxiety and stress, and make it much harder to just live in the moment. There is a truly bewildering variety of cannabis products today, but many of them fall under three categories: inhalation, oral, and topical.

CBD 75

CBD Microdosing Edibles Sleep 75

Cannabis Law Report

JANUARY 11, 2019

Food and Drug Administration (FDA) retains its authority to regulate ingestible and topical products, including those that contain hemp and hemp extracts such as CBD. 9] While that portion of the statement provoked a few breathless media reports, it was old news. The FDA’s position on CBD is unsettled and unsupported by law.

Hemp 49

Hemp CBD Law Seed-To-Sale 49

The Blunt Truth

AUGUST 13, 2019

The FDA explained that Curaleaf’s products, advertised both through its online store and on social media sites, were aimed at the “diagnosis, cure, mitigation, treatment, or prevention of disease and/or intended to affect the structure or any function of the body.” Under section 331(ll) of the FD&C Act (21 U.S.C. First, Sens.

CBD 80

CBD Food Seed-To-Sale Wellness and Beauty 80

Cannabis Law Report

DECEMBER 20, 2021

(“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., Media: Laura Radocaj. Chipman, CPA. Chief Financial Officer. cchipman@virpaxpharma.com 610-727-4597.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Data 52

Cannabis Law Report

JULY 24, 2019

1 We have also reviewed your social media websites at www.facebook.com/CuraleafHemp External Link Disclaimer and [link] External Link Disclaimer ; these websites direct consumers to your website, [link] External Link Disclaimer , to purchase your products. Anxiety, depression, post-traumatic stress disorders, and even schizophrenia.

CBD 51

CBD Tincture Pets Chronic Pain 51

Cannabis Law Report

NOVEMBER 24, 2019

Dr. Griffiths and Dr. Johnson will be speaking at Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks conference in Washington DC. The award is in part based on his media appearances regarding psychedelic research. ANOREXIA NERVOSA. ALZHEIMER’S DISEASE. Upcoming Events.

Therapy 59

Therapy Treatment Medicine Clinical Trials 59

Project CBD

FEBRUARY 28, 2023

In December 2021, Leafreport, an online CBD resource owned by Empire Media Network, published the results of analyses of 221 CBD products it sent to third-party laboratories for testing. The labs analyzed 35 oils, 40 topical products, 40 edibles, 22 beverages, 55 pet products, and 29 coffee or tea products. Accessed October 17, 2022.

CBD 144

CBD Seed-To-Sale Food Access 144

FloridaMarijuana.net

AUGUST 13, 2018

Even mainstream media has delved into the medicinal properties of cannabis and the science-based culture that cannabis heals. Patient self-reporting and clinical trials are the most efficient methods of understanding how well medical cannabis can help even those with severe symptoms related to anxiety and anxiety disorders.

Marijuana 145

Marijuana Patients Clinical Trials Conditions 145

Cannabis Law Report

DECEMBER 8, 2021

Charles River Laboratories, a renowned CRO engaged by Virpax to perform Food and Drug Administration (FDA) required pre-clinical studies, has completed a single dose pharmacokinetic study of dermal administration of Epoladerm in minipigs as part of the required Investigational New Drug Application (“IND”) enabling trials.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Topical 52

FloridaMarijuana.net

OCTOBER 19, 2018

Even mainstream media has delved into the medicinal properties of cannabis and the science-based culture that cannabis heals. Patient self-reporting and clinical trials are the most efficient methods of understanding how well medical cannabis can help even those with severe symptoms related to depression.

Marijuana 189

Marijuana Research and Development Patients Clinical Trials 189

Cannabis Law Report

MARCH 29, 2020

When companies, individuals or groups conduct or commission research of any kind on cannabis product one or more of its various forms (edibles, topicals, beverages, etc.) Others have faced the wrath of their consumers, media, and everyone in their supply chain networks for not complying with Health Canada’s standards and the Cannabis Act.

Compliance 69

Compliance Compliance Supply Chain Research and Development 69

Cannabis Law Report

DECEMBER 28, 2021

Epoladerm™ Epoladerm is a diclofenac topical spray film product candidate that is being developed for pain associated with osteoarthritis of the knee. Epoladerm™ is a topical diclofenac spray film formulation being developed to manage pain associated with osteoarthritis of the knee. Media: Laura Radocaj.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

NOVEMBER 10, 2021

Epoladerm™ is a topical diclofenac spray film formulation being developed to manage osteoarthritis pain. Media: Laura Radocaj. Virpax is developing branded product candidates for non-addictive pain management and neurological disorders using its proprietary technologies to optimize and target drug delivery. Christopher M.

Research and Development 52

Research and Development Chronic Pain Pharmaceutical Clinical Trials 52

Puff Puff Post

SEPTEMBER 16, 2019

Clinical toolkits to help navigate patient assessment and follow-ups. “A significant issue preventing the consideration of cannabinoid medicine by healthcare professionals is that the topic is not typically included in the medical school curriculum,” comments Dr. Mark Ware, Chief Medical Officer, Canopy Growth.

Programs 108

Programs Research and Development Education Treatment 108

Otherside Farms

NOVEMBER 3, 2019

The “entourage effect” is the latest buzz in cannabis media, presenting a well-formed scientific hypothesis that cannabinoids don’t just work on their own. The research on the topic of the entourage effect is scarce, at least in terms of pre-clinical trials. What we don’t know.

Terpenes 58

Terpenes CBD Research and Development Cannabinoids 58

Cannabis Law Report

NOVEMBER 24, 2021

Media representations can offer insights into the nature of the discourse about new medical products and therapies and how ideas and understandings about social phenomena become constructed. This article analyses media representations of medicinal cannabis in Australian medical publications. Media framing of cannabis.

Research and Development 52

Research and Development Medicine Access Media 52

Puff Puff Post

SEPTEMBER 16, 2019

Clinical toolkits to help navigate patient assessment and follow-ups. “A significant issue preventing the consideration of cannabinoid medicine by healthcare professionals is that the topic is not typically included in the medical school curriculum,” comments Dr. Mark Ware, Chief Medical Officer, Canopy Growth.

Programs 40

Programs Research and Development Education Treatment 40

Cannabis Law Report

FEBRUARY 28, 2020

The feeling of “we’re all going to get rich” soon began to permeate through almost every Bitcoin conference and event as mainstream media attention grew, and once the sheen came off and businesses began to pivot to blockchain, there was an air of desperation. We’re not all going to get rich. Perhaps we can rectify this in the Second Edition?

Law 59

Law Research and Development Recreational Cannabis 59

The Cannigma

APRIL 8, 2021

That there’s not enough information about, there’s not enough clinical trials, and there’s not enough this and that. They get pumped out through the media and everybody’s talking about how dangerous it is. All the caines came from cocaine. Plants have always been the source of our medicine, Michael.

Medicine 108

Medicine Cannabinoids Cannabis THC 108

Cannabis Law Report

JUNE 4, 2021

Our proprietary ranking system takes into account: Social reach (social media, blogs, podcasts, publications, etc.). Through his social media outlets, podcast, blog, and interviews, Tim has educated hundreds of millions of people about psychedelics. This list is focused on those who have had the largest impact for 2021. . Followers.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51

SpeedWeed

SEPTEMBER 16, 2021

Many cities have decriminalized psychedelics, and the state of Oregon has decriminalized all drugs and is currently setting up a framework for administering psilocybin in a clinical setting. A clinical trial on MDMA is set to finish in 2022, which could lead to FDA approval. I have a full, rich life, that’s all that is.

Education 86

Education Decriminalization Research and Development Clinical Trials 86